SoftServe Acknowledged as a Major Contender in Healthcare Analytics Services by Everest Group
7.12.2021 15:05:00 EET | Business Wire | Press release
SoftServe, a leading digital authority and consulting company, has been recognized by Everest Group as a Major Contender in healthcare analytics services, according to Everest Group’s Healthcare Analytics Services PEAK Matrix® Assessment 2022. The recognition marks the first year that SoftServe has participated in Everest Group’s annual assessment of the healthcare analytics services marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005472/en/
SoftServe Positioned as a Major Contender in Healthcare Analytics Services by Everest Group (Graphic: Business Wire)
“Our positioning as a Major Contender in Healthcare Analytics is a validation of our strong healthcare domain and technology expertise and of our ability to accelerate business outcomes across the healthcare landscape,” said Adam Gabrault, Executive Vice President of Healthcare and Life Sciences at SoftServe. “We are thankful to our customers for their partnership and will continue on our unwavering commitment to delivering value to our healthcare clients as a trusted adviser and technology partner that enables them to keep their data-driven decision making in sync with evolving demands of the healthcare ecosystem.”
The Healthcare Analytics Services PEAK Matrix Assessment 2022 focuses on the market trends for healthcare analytics services and provides a comparative assessment of 25 service and technology providers based on such factors as vision, capabilities/functionality, talent availability, market success/impact, and cost. The assessment is based on Everest Group's annual RFI process for the calendar year 2021 and includes interactions with leading service providers, client reference checks, and ongoing analysis of the healthcare analytics services market.
SoftServe was positioned as a Major Contender due to its strong execution capabilities across the analytics value chain and a good mix of platforms spanning the entire analytics space from data management to advanced analytics. Everest Group also mentions SoftServe’s investments in strengthening professional expertise through SoftServe University, professional certifications, and a dedicated Center of Excellence. The report also highlights clients’ acknowledgment of SoftServe’s delivery excellence and the quality of its talent as its major strengths.
“Analytics has emerged as a secular theme for healthcare enterprises, as they make their shift towards value-based care, a better stakeholder experience, and improved quality of care. Enterprises are now using it for improved financial and care outcomes, as well as for operational efficiency," said Chunky Satija, Practice Director at Everest Group. "SoftServe, with its investments in building platforms and accelerators such as Human360º platform and Patient Leakage Analytics is well-positioned to assist enterprises in their analytics journey. Its IP-led portfolio of offerings, accompanied by strong execution capabilities and quality of talent has enabled it to be positioned as a Major Contender in Everest Group’s Healthcare Analytics Services PEAK Matrix® Assessment 2022.”
View an extract of the Healthcare Analytics Services PEAK Matrix Assessment 2022 here. To learn more about SoftServe’s healthcare offerings, please visit its Healthcare & Life Sciences page.
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005472/en/
Contact information
SoftServe Media Contacts
Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
Andrew Kavka
Lead Analyst and Public Relations Specialist
akavk@softserveinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 16:00:00 EEST | Press release
GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by various research labs, AIDO Cell is the first to integrate the entire molecular-to-cellular spectrum into one continuous simulation. Using the system
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 16:00:00 EEST | Press release
Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance. Verified creators, less guesswork. Automated anti-fraud vetting and identity verification at payout means developers partner with rea
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 15:48:00 EEST | Press release
The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCCA) The standout feature of this year’s joint pavilion is its overwhelming genre diversity. The lineup includes roguelike deckbuilders, visual novels, 2D shooters, rhythm action, and cooperative horror survival—catering to a broad spectrum of gamers—alongside immersive content that integrates AI and XR technology. Introducing the Participating T
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 15:06:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase recovery from existing infrastructure and support BSP’s long-term production objectives.” The project marks t
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom